ebooks logo journals logo reference works logo abstract databases logo
bullet  SIGN IN Register | Why Register? | Got a Voucher? alerts   marked lists   shopping cart 
Advert: Informa Healthcare - http://www.informahealthcare.com

informaworld

HOME   |   SEARCH   |   BROWSE
    Issues List       Latest Issue       Forthcoming Articles       Volume 9 Issue 1       Subscribe       Article       References       Related articles      
<< firstfirst   < prevprev   Table of contentstoc   next >next   last >>last
Publisher Logo Publication Cover
Search within this journal

Neuronal loss associated with cognitive performance in amyotrophic lateral sclerosis: An (11C)-flumazenil PET study 

Authors: Paul Wicks a;  Martin R. Turner b;  Sharon Abrahams c;  Alexander Hammers d;  David J. Brooks d;  P. Nigel Leigh e; Laura H. Goldstein a
Affiliations:   a MRC Centre for Neurodegeneration Research, King's College London, Institute of Psychiatry, Department of Psychology, London
b Department of Neurology, The Radcliffe Infirmary, Oxford
c Department of Psychology, PPLS, The University of Edinburgh, Edinburgh
d Division of Neuroscience and MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, Hammersmith Hospital, London
e MRC Centre for Neurodegeneration Research, King's College London, Institute of Psychiatry, Department of Clinical Neuroscience, London, UK
DOI: 10.1080/17482960701737716
Publication Frequency: 6 issues per year
Published in: journal Amyotrophic Lateral Sclerosis, Volume 9, Issue 1 2008 , pages 43 - 49
Subject: Neurology;
Formats available: HTML (English) : PDF (English)
Previously published as: Amyotrophic Lateral Sclerosis and other Neuron Disorders (1466-0822, 1471-180X) until 2006
Article Requests: Order Reprints : Request Permissions


Abstract

Amyotrophic lateral sclerosis (ALS) is a multi-system disorder. Mild cognitive deficits are present in a subgroup of non-demented patients with ALS. Detailed neuropsychological assessments reveal deficits of word retrieval including impairments on tests of verbal fluency and confrontation naming. The PET GABAA receptor ligand [11C]-flumazenil is a marker of neuronal dysfunction in ALS. This study used [11C]-flumazenil PET to identify correlations between cortical regions and impairments in word retrieval. Twelve patients with ALS underwent [11C]-flumazenil PET and neuropsychological assessment, including tests of written letter fluency and confrontation naming. Poorer performance on verbal fluency correlated with decreased [11C]-flumazenil binding in a region including the right inferior frontal gyrus, superior temporal gyrus, and anterior insula. Poorer performance on a test of confrontation naming correlated with decreased binding in the left middle frontal gyrus (extending to Broca's area) and left cuneus. This study indicates that [11C]-flumazenil PET can be used to help localize cortical regions associated with cognitive deficits in ALS.
Keywords: ALS; MND; neuroimaging; executive function; PET; verbal fluency; confrontation naming
view references (29)
Bookmark with:
  • CiteULike
  • Del.icio.us
  • BibSonomy
  • Connotea
  • More bookmarks
Privacy Policy | Terms & Conditions | Accessibility | RSS
FAQs in: English . Français . Español . 中文(简体和繁體)
© 2009 Informa plc